Revista Portuguesa de Endocrinologia Diabetes e Metabolismo is a pivotal journal dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Published by the esteemed SOC PORTUGUESA ENDOCRINOLOGIA, DIABETES & METABOLISMO-SPEDM, this journal serves as a platform for the dissemination of high-quality research, clinical studies, and innovative practices within these related disciplines. With a commitment to providing insightful and impactful content, the journal aims to foster knowledge sharing among researchers, healthcare professionals, and students interested in the latest developments in endocrine disorders and metabolic diseases. Although currently not open access, the journal's comprehensive approach and rigorous peer-review process ensure that it remains a respected source of information for its readers in Portugal and beyond. With its address rooted in the heart of Lisbon, the Revista Portuguesa de Endocrinologia Diabetes e Metabolismo plays a vital role in enhancing the understanding and treatment of endocrine and metabolic conditions in the modern healthcare landscape.

Expert Review of Endocrinology & Metabolism is a premier journal dedicated to advancing the field of endocrinology and metabolism, published by Routledge Journals, Taylor & Francis Ltd, in the United Kingdom. With a robust focus on the latest research, innovative treatments, and clinical practices, this journal serves as an essential resource for healthcare professionals, researchers, and students seeking to stay abreast of developments in diabetes, obesity, thyroid disorders, and other endocrine-related conditions. Achieving a commendable Q2 status in Endocrinology, Diabetes, and Metabolism in the 2023 ranking, Expert Review of Endocrinology & Metabolism holds strong standing with an impressive Scopus rank, placing it at the 53rd percentile among its peers. The journal embraces a comprehensive approach, offering critical reviews, original research articles, and insights on emerging trends and technologies in the field. Although not an open-access journal, it provides extensive access options for subscribers and institutions, encouraging ease of dissemination and academic engagement. Through its commitment to high-quality content, Expert Review of Endocrinology & Metabolism remains pivotal for professionals aiming to enhance their understanding and practice in this vital area of medicine.

EUROPEAN JOURNAL OF ENDOCRINOLOGY, published by Oxford University Press, stands as a premier international platform dedicated to advancing research in the burgeoning field of endocrinology, diabetes, and metabolism. Since its inception in 1994, this esteemed journal has gained recognition for its rigorous peer-reviewed articles and innovative studies, evidenced by its impressive Q1 rankings across multiple categories, including Endocrinology and Medicine. With a focus on disseminating critical findings and fostering interdisciplinary collaboration, the journal ranks 33rd out of 244 in Endocrinology, Diabetes, and Metabolism, and 20th out of 128 in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics, positioning it in the top percentiles for researchers worldwide. Although it does not offer open access, the journal remains a vital resource for academics and practitioners alike who seek to stay at the forefront of endocrine research. The EUROPEAN JOURNAL OF ENDOCRINOLOGY continues to push the boundaries of knowledge, driving forward the understanding of complex hormonal functions and their clinical implications.

Minerva Endocrinology, published by EDIZIONI MINERVA MEDICA in Italy, serves as a pivotal platform for advancing knowledge in the field of endocrinology, diabetes, and metabolism. With its ISSN 2724-6507 and E-ISSN 2724-6116, the journal has rapidly established a reputable position in academia, achieving impressive rankings such as Q3 in both Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as of 2023. This enables Minerva Endocrinology to attract a diverse readership, including researchers, healthcare professionals, and students committed to understanding the complexities of endocrine disorders. With annual publications covering breakthroughs and innovative research covering converged years from 2021 to 2024, the journal is devoted to facilitating the dissemination of high-quality studies that advance clinical and laboratory practices. Despite its >Open Access< status, the journal encourages submissions that reflect rigorous scientific inquiry and uphold the highest standards of scholarship, thereby enhancing its role as a significant contributor to the field of internal medicine and endocrinology.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

BMC Endocrine Disorders is a leading open-access journal dedicated to advancing the field of endocrinology, diabetes, and metabolism. Published by BMC since 2001, this journal provides a vibrant platform for researchers to disseminate their findings across a wide array of topics related to endocrine health and disorders. With an impressive Q2 category ranking in both Endocrinology, Diabetes and Metabolism, and Medicine (miscellaneous) for 2023, it has positioned itself among the top-tier journals in its field, reflecting its commitment to high-quality research and discussions. The journal's accessibility enhances its reach and impact, ensuring that important findings are available to all stakeholders in the medical community. Researchers, healthcare professionals, and students alike will find valuable insights and updates that are crucial for both academic and practical applications within this dynamic field. The journal is actively welcoming submissions through 2024, facilitating continuous growth in the scientific discourse surrounding endocrine disorders.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, published by Springer, is a leading journal in the field of endocrinology, diabetes, and metabolism, with an impressive Q1 ranking in both categories as of 2023. With an ISSN of 1389-9155 and E-ISSN 1573-2606, this journal serves as a vital resource for researchers, clinicians, and students seeking comprehensive reviews that address the latest advancements and interdisciplinary approaches in the management of endocrine and metabolic disorders. Operating from the Netherlands, it features articles that are rigorously peer-reviewed and is notable for its significant impact factor reflected in its Scopus rankings, placing it in the top percentile of its categories. Although it does not currently offer open access, it provides critical insights applicable to both basic and clinical settings, making it indispensable for those dedicated to enhancing patient outcomes in endocrine health.

Austrian Journal of Clinical Endocrinology and Metabolism, published by SPRINGER WIEN, serves as a pivotal platform for the dissemination of research in the field of endocrinology, diabetes, and metabolism. With its ISSN 1998-7773 and E-ISSN 1998-7781, this journal has been contributing valuable insights to the field since its inception in 2010. Although it currently holds a Q4 ranking in the category of Endocrinology, Diabetes and Metabolism, it is committed to improving its impact factor by showcasing high-quality, peer-reviewed articles that reflect contemporary challenges and innovations in clinical endocrinology. Located in Vienna, Austria, the journal aims to provide researchers, healthcare professionals, and students with access to the latest findings and clinical practices that advance understanding and treatment of endocrine disorders. Researchers interested in submitting their work will find a supportive environment that embraces both experimental and clinical approaches. The Austrian Journal of Clinical Endocrinology and Metabolism is poised to become a valuable resource for those dedicated to improving health outcomes in metabolic disorders.

Diabetes & Metabolic Syndrome-Clinical Research & Reviews is a leading peer-reviewed journal published by ELSEVIER SCI LTD in the field of endocrinology, diabetes, and internal medicine. With an impressive impact factor evidenced by its high rankings, this journal is positioned in the top quartile (Q1) across multiple categories, including Endocrinology, Diabetes and Metabolism, and Internal Medicine. Spanning from 2007 to 2024, it serves as a vital resource for researchers, healthcare professionals, and students alike, offering comprehensive reviews and innovative clinical research related to metabolic disorders. Located in the Netherlands, the journal emphasizes an open-access approach, ensuring valuable insights are available to a global audience. By publishing high-quality and impactful articles, Diabetes & Metabolic Syndrome not only contributes to the advancement of scientific knowledge but also plays a crucial role in shaping clinical practices and enhancing patient care in the realm of diabetes and metabolic syndrome.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.